PPARγ Agonist Composition for Kidney Disease With Fewer Side Effects

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing PPARγ agonists, such as thiazolidinediones, are associated with side effects like weight gain, edema, and increased risk of heart failure, while glomerular diseases like nephrotic syndrome are refractory to treatment and progress to chronic kidney disease.

Innovation Solution

Administering a PPARγ agonist like GQ-16, which binds to PPARγ in a distinct manner, reducing proteinuria, hypercoagulopathy, and hypoalbuminemia, and stabilizing the β-sheet region to inhibit Ser-273 phosphorylation, thereby treating or preventing glomerular and chronic kidney diseases.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional PPARγ agonists (thiazolidinediones) are used to treat glomerular disease, then proteinuria and glomerular injury are reduced, but weight gain, edema, and increased risk of heart failure occur

Engineering Contradiction:

Improvetreatment efficacyVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent modifies the chemical structure of PPARγ agonists by replacing the thiazolidinedione core with a pyrimidine or triazine ring system, and by altering substituent groups at specific positions (R1-R6). These structural parameter changes result in compounds that maintain PPARγ binding affinity and antiproteinuric effects while reducing activation of pathways leading to weight gain and edema

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces specific substituent groups at defined positions on the heterocyclic ring structure to create localized chemical modifications. These local structural changes (e.g., fluorine atoms at R3, specific alkyl groups at R4) selectively enhance kidney protective effects while minimizing systemic side effects through differential tissue distribution and receptor interaction

Inventive Principle:

Principle #3Local quality

2Ease of operation

If existing treatments for nephrotic syndrome are used, then some symptom relief is achieved, but the disease progresses to chronic kidney disease and end-stage kidney disease

Engineering Contradiction:

Improvesymptom reliefVSAvoiddisease progression prevention

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent employs PPARγ agonists that pre-activate protective pathways in podocytes before irreversible kidney damage occurs. The compounds stabilize podocyte structure and function early in the disease process, preventing progression to chronic kidney disease rather than merely treating established symptoms

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent uses PPARγ receptor activation as an intermediary mechanism to translate chemical compound administration into multiple protective effects. The activated PPARγ receptor mediates anti-inflammatory, antioxidant, and anti-fibrotic effects that collectively prevent disease progression while providing symptom relief

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS12569472B2PPARγ agonists for treatment of kidney disease

Publication Date: 2026.03.10 RES INST AT NATIONWIDE CHILDRENS HOSPITAL

AI summary

A method of treating or preventing glomerular disease or chronic kidney disease in a subject is described. The method includes administering to the subject a therapeutically effective amount of PPARγ agonist or a pharmaceutically acceptable salt thereof.